Exact Mass: 903.4378

Exact Mass Matches: 903.4378

Found 31 metabolites which its exact mass value is equals to given mass value 903.4378, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Dol-P-GlcNAc-Glc-2,3-diNAcA

Dol-P-GlcNAc-Glc-2,3-diNAcA

C43H74N3O15P (903.4857)


   

Des-arg(9)-bradykinin

2-[(1-{2-[2-(2-{[1-(1-{2-amino-5-[(diaminomethylidene)amino]pentanoyl}pyrrolidine-2-carbonyl)pyrrolidin-2-yl]formamido}acetamido)-3-phenylpropanamido]-3-hydroxypropanoyl}pyrrolidin-2-yl)formamido]-3-phenylpropanoic acid

C44H61N11O10 (903.4603)


   

PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/LTE4)

(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-3-{[(2R)-1-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyloxy]-3-(phosphonooxy)propan-2-yl]oxy}-3-oxopropyl]sulfanyl}-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C48H74NO11PS (903.472)


PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/LTE4) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/LTE4), in particular, consists of one chain of one 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl at the C-1 position and one chain of Leukotriene E4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(LTE4/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-3-[(2R)-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyloxy]-3-(phosphonooxy)propoxy]-3-oxopropyl]sulfanyl}-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C48H74NO11PS (903.472)


PA(LTE4/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(LTE4/22:6(4Z,7Z,10Z,13Z,16Z,19Z)), in particular, consists of one chain of one Leukotriene E4 at the C-1 position and one chain of 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

[des-Arg9]bradykinin

[des-Arg9]bradykinin

C44H61N11O10 (903.4603)


   
   

Dehydrodolastatin 13

Dehydrodolastatin 13

C46H61N7O12 (903.4378)


   

cyclo-[DHMHDA-L-Ser-D-Ala-D-Asp-L-Ala-D-Ser-D-Ser-D-allo-Thr]|phaeofungin

cyclo-[DHMHDA-L-Ser-D-Ala-D-Asp-L-Ala-D-Ser-D-Ser-D-allo-Thr]|phaeofungin

C40H69N7O16 (903.4801)


   

(des-arg9)-Bradykinin

(Des-Arg9)-Bradykinin acetate salt

C44H61N11O10 (903.4603)


   

Bradykinin Fragment 2-9

Bradykinin Fragment 2-9

C44H61N11O10 (903.4603)


Bradykinin (2-9) is an amino-truncated Bradykinin peptide. Bradykinin (2-9) is a metabolite of Bradykinin, cleaved by Aminopeptidase P.

   

Pyr-Asp-Pro-Phe-Leu-Arg-Phe-NH2

Pyr-Asp-Pro-Phe-Leu-Arg-Phe-NH2

C44H61N11O10 (903.4603)


Phe-Met-Arg-Phe Like Peptide, Snail Helix aspersa is a FMRF-like peptide from visceral and somatic muscles of the snail Helix aspersa. FMRF (Phe-Met-Arg-Phe) is a neuropeptide peptide consisting of 4 amino acid residues[1].

   

PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/LTE4)

PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/LTE4)

C48H74NO11PS (903.472)


   

PA(LTE4/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

PA(LTE4/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

C48H74NO11PS (903.472)


   

[Des-Arg9]-BRADYKININ

(Des-Arg9)-Bradykinin acetate salt

C44H61N11O10 (903.4603)


   

(2S,3S,4R,5R,6R)-4,5-diacetamido-6-[(2R,3S,4R,5R,6R)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-[hydroxy-[(6Z,10E,14E)-3,7,11,15,19-pentamethylicosa-6,10,14-trienoxy]phosphoryl]oxyoxan-4-yl]oxy-3-hydroxyoxane-2-carboxylic acid

(2S,3S,4R,5R,6R)-4,5-diacetamido-6-[(2R,3S,4R,5R,6R)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-[hydroxy-[(6Z,10E,14E)-3,7,11,15,19-pentamethylicosa-6,10,14-trienoxy]phosphoryl]oxyoxan-4-yl]oxy-3-hydroxyoxane-2-carboxylic acid

C43H74N3O15P (903.4857)


   

H-Arg-Pro-Pro-Gly-Phe-Ser-DL-Pro-Phe-OH

H-Arg-Pro-Pro-Gly-Phe-Ser-DL-Pro-Phe-OH

C44H61N11O10 (903.4603)


   

(6Z,9Z,12Z,15Z)-N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxyoct-4-en-2-yl]octadeca-6,9,12,15-tetraenamide

(6Z,9Z,12Z,15Z)-N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxyoct-4-en-2-yl]octadeca-6,9,12,15-tetraenamide

C44H73NO18 (903.4827)


   

(4Z,7Z,10Z,13Z)-N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxydec-4-en-2-yl]hexadeca-4,7,10,13-tetraenamide

(4Z,7Z,10Z,13Z)-N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxydec-4-en-2-yl]hexadeca-4,7,10,13-tetraenamide

C44H73NO18 (903.4827)


   

(3Z,6Z,9Z,12Z,15Z)-N-[1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxyoctan-2-yl]octadeca-3,6,9,12,15-pentaenamide

(3Z,6Z,9Z,12Z,15Z)-N-[1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxyoctan-2-yl]octadeca-3,6,9,12,15-pentaenamide

C44H73NO18 (903.4827)


   

H-Arg-Pro-Pro-Gly-D-Phe-Ser-DL-Pro-Phe-OH

H-Arg-Pro-Pro-Gly-D-Phe-Ser-DL-Pro-Phe-OH

C44H61N11O10 (903.4603)


   

H-Pro-Pro-Gly-D-Phe-Ser-D-Pro-D-Phe-D-Arg-OH

H-Pro-Pro-Gly-D-Phe-Ser-D-Pro-D-Phe-D-Arg-OH

C44H61N11O10 (903.4603)


   

Hex3Cer 26:5;O2

Hex3Cer 26:5;O2

C44H73NO18 (903.4827)


   

Acetyl-PHF6 amide (TFA)

Acetyl-PHF6 amide (TFA)

C40H64F3N9O11 (903.4677)


Acetyl-PHF6 amide TFA (AcPHF6 TFA) is a tau derived hexapeptide.

   

(2s)-2-{[(2r)-2-{[(2s)-2-[(2-{[2-({[(2s)-1-[(2r)-2-{[(2s)-2-{[(2s)-2,6-diamino-1-hydroxyhexylidene]amino}-1-hydroxy-4-methylpentylidene]amino}-3-sulfanylpropanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-1-hydroxyethylidene]amino}-1-hydroxyethylidene)amino]-1-hydroxy-4-(c-hydroxycarbonimidoyl)butylidene]amino}-1-hydroxy-3-sulfanylpropylidene]amino}-3-methylbutanoic acid

(2s)-2-{[(2r)-2-{[(2s)-2-[(2-{[2-({[(2s)-1-[(2r)-2-{[(2s)-2-{[(2s)-2,6-diamino-1-hydroxyhexylidene]amino}-1-hydroxy-4-methylpentylidene]amino}-3-sulfanylpropanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-1-hydroxyethylidene]amino}-1-hydroxyethylidene)amino]-1-hydroxy-4-(c-hydroxycarbonimidoyl)butylidene]amino}-1-hydroxy-3-sulfanylpropylidene]amino}-3-methylbutanoic acid

C37H65N11O11S2 (903.4306)


   

(2r)-2-({3-[(2-{[(2r)-2-{[(2s)-2-{[(2r)-2-[(3-amino-1-hydroxy-4-methyl-7-phenylhept-6-en-1-ylidene)amino]-1,3-dihydroxypropylidene]amino}-1,3-dihydroxybutylidene]amino}-1-hydroxy-3-(4-methoxyphenyl)propylidene]amino}-1-hydroxyethylidene)amino]-1-hydroxy-2-methylpropylidene}amino)-3-(4-hydroxyphenyl)propanoic acid

(2r)-2-({3-[(2-{[(2r)-2-{[(2s)-2-{[(2r)-2-[(3-amino-1-hydroxy-4-methyl-7-phenylhept-6-en-1-ylidene)amino]-1,3-dihydroxypropylidene]amino}-1,3-dihydroxybutylidene]amino}-1-hydroxy-3-(4-methoxyphenyl)propylidene]amino}-1-hydroxyethylidene)amino]-1-hydroxy-2-methylpropylidene}amino)-3-(4-hydroxyphenyl)propanoic acid

C46H61N7O12 (903.4378)


   

[(3r,6r,9r,12s,15r,18r,21s)-5,8,11,14,17,20,23-heptahydroxy-3-[(1r)-1-hydroxyethyl]-6,9,21-tris(hydroxymethyl)-25-(2-hydroxytetradecan-2-yl)-12,18-dimethyl-2-oxo-1-oxa-4,7,10,13,16,19,22-heptaazacyclopentacosa-4,7,10,13,16,19,22-heptaen-15-yl]acetic acid

[(3r,6r,9r,12s,15r,18r,21s)-5,8,11,14,17,20,23-heptahydroxy-3-[(1r)-1-hydroxyethyl]-6,9,21-tris(hydroxymethyl)-25-(2-hydroxytetradecan-2-yl)-12,18-dimethyl-2-oxo-1-oxa-4,7,10,13,16,19,22-heptaazacyclopentacosa-4,7,10,13,16,19,22-heptaen-15-yl]acetic acid

C40H69N7O16 (903.4801)


   

2-[({3-[(6-bromo-1h-indol-3-yl)methyl]-2,5,11,14-tetrahydroxy-7,12-dimethyl-6,9-bis(2-methylpropyl)-8-oxo-1,4,7,10,13-pentaazacyclononadeca-1,4,10,13-tetraen-15-yl}-c-hydroxycarbonimidoyl)amino]-5-carbamimidamidopentanoic acid

2-[({3-[(6-bromo-1h-indol-3-yl)methyl]-2,5,11,14-tetrahydroxy-7,12-dimethyl-6,9-bis(2-methylpropyl)-8-oxo-1,4,7,10,13-pentaazacyclononadeca-1,4,10,13-tetraen-15-yl}-c-hydroxycarbonimidoyl)amino]-5-carbamimidamidopentanoic acid

C40H62BrN11O8 (903.3966)


   

[5,8,11,14,17,20,23-heptahydroxy-3-(1-hydroxyethyl)-6,9,21-tris(hydroxymethyl)-25-(2-hydroxytetradecan-2-yl)-12,18-dimethyl-2-oxo-1-oxa-4,7,10,13,16,19,22-heptaazacyclopentacosa-4,7,10,13,16,19,22-heptaen-15-yl]acetic acid

[5,8,11,14,17,20,23-heptahydroxy-3-(1-hydroxyethyl)-6,9,21-tris(hydroxymethyl)-25-(2-hydroxytetradecan-2-yl)-12,18-dimethyl-2-oxo-1-oxa-4,7,10,13,16,19,22-heptaazacyclopentacosa-4,7,10,13,16,19,22-heptaen-15-yl]acetic acid

C40H69N7O16 (903.4801)


   

(2s)-2-({[(3s,6s,9s,12s,15r)-3-[(6-bromo-1h-indol-3-yl)methyl]-2,5,11,14-tetrahydroxy-7,12-dimethyl-6,9-bis(2-methylpropyl)-8-oxo-1,4,7,10,13-pentaazacyclononadeca-1,4,10,13-tetraen-15-yl]-c-hydroxycarbonimidoyl}amino)-5-carbamimidamidopentanoic acid

(2s)-2-({[(3s,6s,9s,12s,15r)-3-[(6-bromo-1h-indol-3-yl)methyl]-2,5,11,14-tetrahydroxy-7,12-dimethyl-6,9-bis(2-methylpropyl)-8-oxo-1,4,7,10,13-pentaazacyclononadeca-1,4,10,13-tetraen-15-yl]-c-hydroxycarbonimidoyl}amino)-5-carbamimidamidopentanoic acid

C40H62BrN11O8 (903.3966)